RLRodolfo A. Lizárraga-Valadez

Rodolfo A. Lizárraga-Valadez

*This is an algorithmically generated author record based on publicly available information.

Rodolfo A. Lizárraga-Valadez has a total of 4 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Uncompetitive Allosteric Inhibition of PTP1B by BP-1-102 Reveals a Potential Dual-Target Strategy toward the PTP1B–STAT3 Oncogenic Axis: Biochemical and Computational Evidence

    by Martín González-Andrade, Rodolfo A. Lizárraga-Valadez, Alejandro Sosa-Peinado, Francisco Cortés-Benítez, Nathaly Vasquez-Martínez

    Selective PTP1B inhibitors paradoxically potentiate oncogenic STAT3 signaling by restoring JAK2 activity, underscoring the need for dual-target strategies. Here we report that BP-1-102, an orally bioavailable STAT3 SH2 domain inhibitor, also potently inhibits PTP1B with IC50 values of 5.32 μM (hPTP1B1–400) and 11.7 μM (hPTP1B1–285), with ≥37.7-fold selectivity over TCPTP. Kinetic analysis identified an uncompetitive mechanism, suggesting inhibitor binding to the enzyme–substrate complex at a site distal to the active site. Docking and 500 ns molecular dynamics simulations revealed a dual-anchor binding mode involving the 113–123 loop (Cys121) and the proline-rich C-terminal disordered region, a structural interface absent in TCPTP. Umbrella sampling confirmed favorable passive membrane permeability through a tumor-mimetic bilayer (ΔG = −13.83 kcal/mol). These results propose BP-1-102 as a candidate for dual-function inhibitor of the PTP1B–JAK2–STAT3 oncogenic axis, providing a physicochemical and mechanistic rationale for its further evaluation in tumors where both targets are coactivated.